Cision PR Newswire

Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with...

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the...

Liquid Web Expands Dedicated Server Locations in North America, Europe, and Asia-Pacific to Strengthen Global Reach for Faster, Reliable Hosting

ATLANTA, Feb. 21, 2025 /PRNewswire/ -- Liquid Web, a leader in dedicated servers, WordPress, VPS, GPU, and cloud hosting solutions, has launched four new...

Fosun Joins Hands with Abu Dhabi Investment Office, Adding New Momentum to Middle East Strategy

HONG KONG and SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Fosun's global operations achieved another milestone. On February 20, during the Abu Dhabi Investment Forum in...

Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

HONG KONG, Feb. 21, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient...